Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: Ex vivo gut permeation studies

Nanotechnology

Volumn 24, Issue 41, 2013, Pages

  Neupane, Yub Raj ^a   Sabir, M D ^a   Ahmad, Nafees ^a   Ali, Mushir ^a   Kohli, Kanchan ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL DEGRADATION; CRYSTALLINE STRUCTURE; DEPENDENT VARIABLES; FIRST-ORDER MODELS; HOMOGENIZATION TECHNIQUES; INDEPENDENT VARIABLES; LYOPHILIZED POWDERS; SPHERICAL MORPHOLOGIES;

HOMOGENIZATION METHOD; NONIONIC SURFACTANTS; STEARIC ACID;

NANOPARTICLES;

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG CARRIER; NANOPARTICLE; STEARIC ACID; STEARIC ACID DERIVATIVE; SURFACTANT; DRUG DERIVATIVE;

ANALOGS AND DERIVATIVES; CHEMISTRY; KINETICS; PERMEABILITY; ULTRASTRUCTURE; ARTICLE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DRUG CARRIERS; KINETICS; NANOPARTICLES; PERMEABILITY; STEARIC ACIDS; SURFACE-ACTIVE AGENTS;

EID: 84884648001     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/24/41/415102     Document Type: Article

References (34)

1. Attama A A, Momoh M A and Builders P F 2012 Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development Recent Advances in Novel Drug Carrier Systems (Rijeka: InTech) chapter 5
2. Benita S and Levy M Y 1993 Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization J. Pharm. Sci. 82 1069-79 (Pubitemid 24004434)
3. Carino G P and Mathiowitz E 1999 Oral insulin delivery Adv. Drug Delivery Rev. 35 249-57 (Pubitemid 29073617)
4. Cashen A F, Shah A K, Todt L, Fisher N and DiPersio J 2008 Pharmacokinetics of DCB administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Cancer Chemother. Pharmacol. 61 759-66 (Pubitemid 351302031)
5. Chaudhary H, Kohli K, Amin S, Rathee P and Kumar V 2010 Optimization and formulation design of gels of diclofenac and curcumin for transdermal drug delivery by Box-Behnken statistical design J. Pharm. Sci. 100 580-93
6. Chopra S, Motwani S K, Iqbal Z, Talegaonkar S, Ahmad F J and Khar R K 2007 Optimization of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design Eur. J. Pharm. Biopharm. 67 120-13 (Pubitemid 46991318)
7. DACOGEN® (DCB) 2012 FDA ODAC Briefing Document NDA 021790/S-010 Eisai Inc. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM290512.pdf (accessed on 25/08/12)
8. Emeje M O, Obidike I C, Akpabio E I and Ofoefule S I Recent Advances in Novel Drug Carrier Systems, Nanotechnology in Drug Delivery (Rijeka: InTech) chapter 4
9. Gannu R, Yamsani V V, Yamsani S K, Palem C R and Yamsani M R 2009 Optimization of hydro gels for transdermal delivery of lisinopril by Box-Behnken statistical design AAPS Pharm-SciTech. 10 505-14
10. Garcia J S, Jain N and Godley A L 2010 An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes Onco Targets Therapy 3 1-13
11. Gore S D, Jones C and Kirkpatrick P 2006 Analysis myelodysplastic syndromes Nature Rev. Drug Discov. 5 891-2 (Pubitemid 44660602)
12. Hao J et al 2011 Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design Int. J. Nanomed. 6 683-92
13. Howell P M, Liu Z and Khong H T 2010 Demethylating agents in the treatment of cancer Pharmaceuticals 3 2022-44
14. ICH topic Q1 A (R2) Stability Testing of New Drug Substances and Products (CPMP/ICH/2736/99) www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002651.pdf (accessed on 26 February 2013)
15. Jabbour E, Issa J P, Manero G G and Kantarjian H 2008 Evolution of DCB development accomplishments, ongoing investigations, and future strategies Cancer 112 2341-51
16. Kasongo K W, Pardeike J, Muller R H and Walker R B 2011 Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers J. Pharm. Sci. 100 5185-96
17. Li S, Ji Z, Zou M, Nie X, Shi Y and Cheng G 2011 Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine AAPS PharmSciTech. 12 1011-8
18. Lin Y, Shen Q, Katsumi H, Okada N, Fujita T, Jiang X and Yamamoto A 2007 Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats Biol. Pharm. Bull. 30 1301-7 (Pubitemid 47037658)
19. Liu D 2012 Recent advances in myelodysplasia: update from 2011 ASH annual meeting J. Hematol. Oncol. 5 31
20. Muller R H, Mader K and Gohla S 2000 Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 161-77 (Pubitemid 30326695)
21. Muller R H and Olbrich C 1999 Arzneistoffträger zur kontrollierten Wirkstoffapplikation hergestellt aus nicht-kovalenten Lipidmatrix-Arzneistoff- Konjugaten German Patent Application 199 64 085.8
22. Muller R H, Runge S, Ravelli V, Mehnert W, Thunemann A F and Souto E B 2006 Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals Int. J. Pharm. 317 82-9 (Pubitemid 43866342)
23. Muller R H and Runge S A 1998 Solid lipid nanoparticles (SLN) for controlled drug delivery Submicron Emulsions in Drug Targeting and Delivery ed S Benita (Amsterdam: Harwood Academic) pp 219-34
24. Olbrich C, Gessner A, Kayser O and Muller R H 2002 Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate J. Drug Targeting 10 387-96
25. Olbrich C, Gessner A, Schroder W, Kayser O and Muller R H 2004 Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption J. Control. Release 96 425-35 (Pubitemid 38553921)
26. Pardeikea J, Webera S, Haberb T, Wagnerb J, Zarflc H P, Plankb H and Zimmera A 2011 Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application Int. J. Pharm. 419 329-38
27. Porter C J H, Trevaskis N L and Charman W N 2007 Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nature Rev. Drug Discov. 6 231-48 (Pubitemid 46344627)
28. Ruan L P, Chen S, Yu B Y, Zhu D N, Cordell G A and Qiu S X 2006 Prediction of human absorption of natural compounds by the non-everted rat intestinal SAC model Eur. J. Med. Chem. 41 605-10 (Pubitemid 43766796)
29. Saba H I 2007 Decitabine in the treatment of myelodysplastic syndromes Ther. Clin. Risk Manag. 3 807-17 (Pubitemid 350162080)
30. Souza L G et al 2011 Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release Eur. J. Pharm. Biopharm. 79 189-96
31. Stresemann C and Lyko F 2008 Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int. J. Cancer 123 8-13 (Pubitemid 351705186)
32. Weyhers H, Ehlers S, Hahn H, Souto E B and Muller R H 2006 Solid lipid nanoparticles (SLN)-effect of lipid composition on in vitro degradation and in vivo toxicity Pharmazie 61 539-44 (Pubitemid 43989132)
33. Yang C R et al 2010 Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers Chem. Pharm. Bull. 58 656-61
34. Zhang H, Yao M, Morrison R A and Chong S 2003 Commonly used surfactant, tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats Arch. Pharm. Res. 26 768-72 (Pubitemid 43073795)